Bachem Holding AGBCHMF 91 ROC (Joel Greenblatt) % is 12.95% as of Dec. 2025, which is 3% above its 10-year median of 12.55. GuruFocus rates BCHMF with a GF Score™ of 91/100 and a GF Value™ of $97.63 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,324 Biotechnology companies, Bachem Holding AG ranks better than 83.99% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Bachem Holding AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 12.95%.
The historical rank and industry rank for Bachem Holding AG's ROC (Joel Greenblatt) % or its related term are showing as below:
BCHMF'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 10.17 Med: 12.55 Max: 21.26
Current: 10.2
During the past 13 years, Bachem Holding AG's highest ROC (Joel Greenblatt) % was 21.26%. The lowest was 10.17%. And the median was 12.55%.
BCHMF's ROC (Joel Greenblatt) % is ranked better than 83.99% of 1324
companies
in the Biotechnology industry
Industry Median: -297.06
vs BCHMF: 10.20
Bachem Holding AG's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -13.70% per year.
Bachem Holding AG (OTCPK:BCHMF) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Bachem Holding AG ROC (Joel Greenblatt) % Related Terms
Bachem Holding AG ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Bachem Holding AG's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BCHMF vs VRTX, REGN, ALNY: ROC (Joel Greenblatt) % Comparison
For the Biotechnology subindustry, Bachem Holding AG's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bachem Holding AG ROC (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bachem Holding AG's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Bachem Holding AG's ROC (Joel Greenblatt) % falls into.
Bachem Holding AG ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 12.95% mean?
Bachem Holding AG (BCHMF) has a ROC (Joel Greenblatt) % of 12.95% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Bachem Holding AG and its competitors. This is near median its historical median of 12.55. Over the past decade, Bachem Holding AG's ROC (Joel Greenblatt) % has ranged from 10.17 to 21.26. According to the industry distribution chart, Bachem Holding AG ranks #212 out of 1324 companies in the Biotechnology industry, placing it in the top 16%.
Is Bachem Holding AG's ROC (Joel Greenblatt) % too high?
Bachem Holding AG's current ROC (Joel Greenblatt) % of 12.95% is near median its 10-year median of 12.55. Over the past 10 years, this metric has ranged from a low of 10.17 to a high of 21.26. Based on the distribution chart, Bachem Holding AG ranks #212 out of 1324 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Bachem Holding AG has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bachem Holding AG's ROC (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bachem Holding AG ranks #212 out of 1324 companies for ROC (Joel Greenblatt) %. This places Bachem Holding AG in the top 16% of its industry — outperforming the majority of peers. Historically, Bachem Holding AG's own ROC (Joel Greenblatt) % has ranged from 10.17 to 21.26 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Bachem Holding AG and its competitors. Bachem Holding AG's current ROC (Joel Greenblatt) % is 12.95%, which is near median its own 10-year median of 12.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bachem Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Bachem Holding AG (BCHMF) is currently considered Modestly Undervalued. The stock's GF Value™ is $97.63, compared to a current price of $87.34 — trading 10.5% below its estimated fair value. The current ROC (Joel Greenblatt) % is 12.95%, which is near median its 10-year median of 12.55. Bachem Holding AG's overall GF Score™ is 91/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Bachem Holding AG (BCHMF), the current ROC (Joel Greenblatt) % is 12.95% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bachem Holding AG (BCHMF) Overvalued in 2026?
Based on GuruFocus' analysis, Bachem Holding AG stock appears to be undervalued.
The current stock price of $87.34 is trading 10.5% below its estimated GF Value™ of $97.63.
GuruFocus considers Bachem Holding AG to be Modestly Undervalued.
Key valuation signals for BCHMF:
ROC (Joel Greenblatt) %: 12.95% (near median its 10-year median of 12.55)
GF Value™: $97.63 vs. price of $87.34 (10.5% below fair value)
No single metric tells the full story. See the BCHMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bachem Holding AG is a biochemical company that provides services to the pharmaceutical and biotechnology industry. It focuses on specializing in the development and manufacture of peptides and oligonucleotides. The group markets its products under the Bachem and Clinalfa brands. Its products and services are CMC Development, Commercial API, Research and Specialities, and Services and Capabilities. Geographically, it operates in Switzerland, USA, Ireland, Denmark, United Kingdom, and Rest of the World.
91GF Score
Get the complete analysis for BCHMF
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BCHMF has been successfully added to your 
